ro health glp 1 GLP-1 Medications for Weight Loss with the Body Program Ro Launches GLP-1 Insurance Coverage

Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease

2019 Feb 1

Hayes expects to see more tolerable options emerge within the next two years

The second is a review of new GLP-1 and related drugs currently in clinical trials that could treat a wide range of conditions